Now Playing
Opinion|Videos|August 16, 2024
Expert Perspective on the Expanding Treatment Landscape in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the expanding treament landscape for mCRPC.
Advertisement
Episodes in this series
- Given the evolution/expansion of the prostate cancer treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), can you discuss key factors that shape your treatment approach?
- How do patient characteristics such as age, performance status, and comorbidities influence that decision?
Advertisement
Related to this article
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Advertisement
Advertisement